A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

WILLIAM J. SANDBORN,*,‡ BRIAN G. FEAGAN,§ STEPHEN B. HANAUER,*,‡ HERBERT LOCHS,* ROBERT LOFBERG,* ROBERT MODIGLIANI,*,\ DANIEL H. PRESENT,*,‡ PAUL RUTGEERTS,* JURGEN SCHOLMERICH,* EDUARD F. STANGE,* and LLOYD R. SUTHERLAND* *The Clinical Trials Task Force of the International Organization of Inflammatory Bowel Disease (IOIBD), ‡The Clinical Alliance of the Crohn’s and Colitis Foundation of America, the §Clinical Network of the Crohn’s and Colitis Foundation of Canada, and the \Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives. See Appendix I for institutional affiliations for each author and for the complete membership of the IOIBD Clinical Trials Task Force